Investment Rating - The investment rating for the company is "Buy" (maintained) based on performance review [1]. Core Views - The company's profit performance meets expectations, with overall expense control being effective. In 2023, the company achieved operating revenue of 2.456 billion yuan (+3.35%) and a net profit attributable to shareholders of 348 million yuan (+139.33%). The first quarter of 2024 saw operating revenue of 736 million yuan (+38.40%) and a net profit of 98 million yuan (+90.95%) [4]. - The sales of Ensartinib have rapidly increased, and new drug launches in 2024 are anticipated to contribute significantly to revenue. In 2023, the sales of Alectinib remained stable, while Ensartinib was included in medical insurance for both first-line and second-line indications, leading to rapid growth. The company launched two new drugs in 2023, with the third-generation EGFR-TKI, Bevacizumab, approved for both indications, and the first innovative small molecule drug for kidney cancer, Voronib, also approved [4]. - The R&D pipeline continues to advance, with both internal development and external collaborations. In 2023, the company invested 1.002 billion yuan in R&D, accounting for 40.80% of revenue. The company has over 20 projects in development, with significant progress in clinical trials for various treatments [4]. Summary by Sections Financial Performance - In 2023, the company reported total operating revenue of 2,456 million yuan, with a growth rate of 3.35%. The net profit attributable to shareholders was 348 million yuan, reflecting a growth rate of 139.33% [7]. - The company forecasts revenues of 3.064 billion yuan, 3.893 billion yuan, and 4.917 billion yuan for 2024, 2025, and 2026, respectively, with corresponding net profits of 407 million yuan, 540 million yuan, and 711 million yuan [5][8]. R&D and Product Pipeline - The company has a robust R&D pipeline with over 20 projects, and R&D expenses accounted for 40.80% of revenue in 2023. The company is actively pursuing collaborations to enhance its product offerings [4][5]. Market Position and Future Outlook - The company is well-positioned in the market with a diverse product pipeline and strong growth potential from new drug launches. The anticipated revenue growth from new products and effective expense management supports a positive outlook for the company [4][5].

Investment Rating - The investment rating for the company is "Buy" [3][8] - The rating is maintained without any changes [3] Core Views - The company has returned to a growth trajectory with significant revenue and profit increases, driven by the rapid launch of its product Beimeina and contributions from new products [2][4] - The company's revenue for 2023 reached 2.456 billion yuan, a year-on-year increase of 3.35%, while the net profit attributable to shareholders was 348 million yuan, up 139.33% [3][4] - In Q1 2024, the company achieved revenue of 736 million yuan, a 38.40% increase year-on-year, and a net profit of approximately 98.14 million yuan, reflecting a 90.95% growth [3][7] Financial Performance - The company reported a significant decrease in management and financial expenses, with management expenses down 42.49% to 262 million yuan [4] - The net profit attributable to shareholders for 2023 was 263 million yuan, a staggering increase of 768.85% [3][4] - The company expects net profits of 420 million, 547 million, and 665 million yuan for 2024, 2025, and 2026 respectively, with corresponding EPS of 1.00, 1.31, and 1.59 yuan [8][9] Product Development and Pipeline - The product Ensartinib has seen rapid growth and has been included in the National Medical Insurance Directory, significantly enhancing its market accessibility [5][6] - The company has launched two new products, Beifutini and Voronib, which are expected to contribute to future revenue growth [5][6] - The company has over 40 projects in its pipeline, indicating strong long-term growth potential [8]

[Table_StockInfo] 持有 2024年 04月 21日 （维持） 证券研究报告•2023年报及 2024年一季报点评 当前价：3 6.04元 贝达药业（300558） 医 药生物 目标价：— —元（6个月） 贝福替尼有望快速放量，创新管线稳步推进 投资要点 西南证券研究发展中心 [T ab业le绩_S总um结m：a公ry]司 发布 2023 年报和 2024 年一季报，2023 年实现营业收入 24.56亿元（+3.35%），归母净利润 3.48亿元（+139.33%），扣非后归母净利 [分Ta析bl师e_：Au杜th向or阳] 润 2.63 亿元（+768.85%）。2024 年一季度实现营业收入 7.36 亿元 执业证号：S1250520030002 （+38.40），归母净利润 0.98 亿元（+90.95%），扣非后归母净利润 0.9 亿元 电话：021-68416017 （+390.39%）。 邮箱：duxy@swsc.com.cn  贝福替尼有望快速放量，恩莎替尼一线 NDA 获 FDA 受理。2023年，赛美纳 [相Tab对le指_Q数u表ot现eP ic] 二线治疗适应症、一 ...

上 市 公 司 医药生物 2024年04月21日 贝达药业 (300558) 公 司 研 究 ——费用管控合理，多品种拉动增长 公 司 点 报告原因：有业绩公布需要点评 评 买入 投资要点： （维持） ⚫ 事件。公司发布2023年年报和2024年一季报，23年公司实现营业收入24.56亿元（同 比+3.35%），实现归母净利润3.48亿（同比+139.33%），实现扣非归母净利润2.63亿 证 市场数据： 2024年04月19日 （同比+768.65%）。2024年一季度，公司实现营业收入7.36亿（同比+38.40%），实 券 收盘价（元） 36.04 研 一年内最高/最低（元） 73.11/33.11 现归母净利润0.98亿（同比+90.95%），实现扣非归母净利润0.90亿（同比+390.39%）， 究 市净率 2.7 埃克替尼受竞品影响持续下滑，新品上市放量进度低于此前预期，因此公司业绩低于预期。 报 息率（分红/股价） - 告 流通A股市值（百万元） 15034 ⚫ 产品收入结构更加多元化，管理费用和研发费用进一步下降。2023 年公司的营收由 5 款 上证指数/深证成指 3065.26/9279. ...

贝达[Ta药ble业_S（tock 3N 0am 0e 5R 5p 8tT .y Spe Z] ） 公司研究/公司点评 23FY 及 24Q1 延续高增长，多点驱动布局肺癌 [T投 a资 ble评 _R级 a： nk买 ] 入（维持） 主要观点： 报告日期： 2024-04-21 ⚫[T 事ab件le_S1 ummary] [收Ta盘bl价e_（Ba元se）D ata] 36.04 2024年4月20日，贝达药业发布2023年年报，报告期内公司实现营 近12个月最高/最低（元） 73.04/33.11 业收入 24.56 亿元，同比+3.35%；归母净利润 3.48 亿元，同比 总股本（百万股） 418 +139.33%；扣非归母净利润2.63亿元，同比+768.85%。单季度来看， 流通股本（百万股） 417 公司2023Q4收入为4.13亿元，同比-42.20%；归母净利润为0.43亿 流通股比例（%） 99.73% 元，同比+1.70%；扣非归母净利润为0.22亿元，同比+167.24%。 总市值（亿元） 150.82 ⚫ 事件 2 流通市值（亿元） 150.34 2024年4月20日，贝达药业发布20 ...

Investment Rating - The investment rating for the company is "Accumulate" [7]. Core Views - The company's performance in 2023 and Q1 2024 met expectations, driven by new drug launches and inclusion in medical insurance [2][3]. - Significant revenue growth was observed from the sales of Beimu and Beanting, with Beimu's revenue increasing by 116% year-on-year in the first three quarters of 2023 [3]. - The company has a strong pipeline with potential growth from targeted therapies and collaborations in ophthalmology [4]. Financial Performance Summary - In 2023, the company achieved revenue of 2.456 billion yuan, a year-on-year increase of 3.35%, and a net profit of 348 million yuan, up 139.33% [2][6]. - For Q1 2024, revenue reached 736 million yuan, reflecting a year-on-year growth of 38.40%, with a net profit of 98 million yuan, up 90.95% [2][6]. - The company expects revenue for 2024-2026 to be 2.709 billion, 3.092 billion, and 3.336 billion yuan, respectively, with growth rates of 10.30%, 14.14%, and 7.90% [5][6]. Valuation and Forecast - The forecast for net profit for 2024-2026 is 274 million, 399 million, and 480 million yuan, with growth rates of -21.27%, 45.73%, and 20.29% respectively [5][6]. - The estimated EPS for the same period is 0.65, 0.95, and 1.15 yuan per share, with a three-year CAGR of 11.32% [5][6]. - The target price is set at 42.61 yuan, based on a 65x PE ratio for 2024 [5].

Financial Performance - Revenue in 2023 increased by 3.35% to 2,456,196,486.62 yuan compared to 2022[10] - Net profit attributable to shareholders surged by 139.33% to 348,032,472.42 yuan in 2023[10] - Operating cash flow grew significantly by 198.05% to 914,227,977.50 yuan in 2023[10] - Basic earnings per share rose by 137.14% to 0.83 yuan in 2023[10] - Total assets increased by 15.64% to 9,146,908,395.53 yuan at the end of 2023[10] - Q2 2023 revenue was the highest at 782,259,420.96 yuan among all quarters[11] - Q3 2023 net profit attributable to shareholders reached 156,386,574.59 yuan, the highest quarterly figure[11] - Revenue for 2023 reached 24.56 billion yuan, a year-on-year increase of 3.35%[39] - Net profit attributable to shareholders was 348.03 million yuan, up 139.33% year-on-year[39] - Non-GAAP net profit was 262.85 million yuan, a significant increase of 768.85% year-on-year[39] - Operating cash flow surged to 914.23 million yuan, up 198.05% year-on-year[41] - Total revenue for 2023 reached 2,456,196,486.62 yuan, a year-on-year increase of 3.35%[56] - Pharmaceutical manufacturing accounted for 100% of total revenue, with drug sales contributing 98.40%[56] - Domestic sales accounted for 99.96% of total revenue, with a year-on-year increase of 3.32%[56] - Gross profit margin for pharmaceutical manufacturing was 83.53%, a decrease of 5.16% compared to the previous year[57] - Sales volume increased by 2.52% to 3,047,651 boxes, while production volume decreased by 15.71% to 3,806,830 boxes[58] - The top five customers accounted for 61.45% of total sales, with the largest customer contributing 31.62%[61] - The top five suppliers accounted for 42.23% of total procurement, with the largest supplier contributing 17.17%[62][63] - Sales expenses increased by 9.61% to RMB 853.89 million in 2023 compared to RMB 779.06 million in 2022[64] - Management expenses decreased by 42.49% to RMB 261.76 million in 2023 due to reduced equity incentive costs[64] - Financial expenses decreased by 77.45% to RMB 39.59 million in 2023 due to reduced interest expenses[64] - R&D expenses decreased by 8.54% to RMB 640.14 million in 2023 compared to RMB 699.90 million in 2022[64] - Operating cash flow increased by 198.05% to 914,227,977.50 yuan, driven by higher cash inflows from drug sales[68] - Investment cash flow net outflow increased by 13.68% to -1,505,452,905.04 yuan, mainly due to the purchase of long-term assets and equity investments[68] - Financing cash flow net inflow decreased by 35.40% to 608,193,350.56 yuan, despite a 79.00% increase in cash inflows from financing activities[68] - Net cash and cash equivalents increased by 134.12% to 20,712,054.82 yuan[68] - Non-operating income accounted for 19.12% of total profit, primarily from compensation payments[70] - Long-term loans increased by 11.56% to 1,816,000,000.00 yuan, reflecting new bank loans during the reporting period[71] - Intangible assets increased by 5.84% to 1,943,510,385.64 yuan, mainly due to the transfer of development costs for newly approved drugs[71] - Overseas assets accounted for 26.25% of the company's net assets, with Xcovery Holdings, Inc. being the largest contributor[72] - The fair value of other equity instrument investments increased by 41,845,298.27 yuan, reaching 1,006,597,002.32 yuan at the end of the period[73] - Total investment during the reporting period increased by 8.30% to 1,705,971,266.15 yuan[74] - The company invested a total of 1,116,240,904.06 yuan in significant equity investments during the reporting period, with a total investment loss of -21,721,933.08 yuan[75] - The company invested 716,490,862.42 yuan in Xcovery Holdings, Inc., holding a 98.44% stake, resulting in a loss of -19,696,491.56 yuan[75] - The company invested 249,750,000.00 yuan in Hangzhou Beicheng Venture Capital Partnership, holding a 49.95% stake, resulting in a loss of -2,025,441.52 yuan[75] - The company invested 150,000,041.64 yuan in Beijing Mabworks Biotech Co., Ltd., holding a 2.91% stake[75] - The company invested a total of 589,730,362.09 yuan in significant non-equity investments during the reporting period, with a cumulative actual investment of 1,958,290,885.25 yuan[76] - The DreamWorks Phase II project has a cumulative investment of 1,313,872,501.95 yuan, with a progress rate of 72.99%[76] - The Shengzhou Innovative Drug Industrialization Base project has a cumulative investment of 644,418,383.30 yuan, with a progress rate of 65.76%[76] - The company's securities investment in AGENUS resulted in a loss of -52,907,243.50 yuan, with an ending book value of 28,595,124.38 yuan[77] - The company invested 150,000,041.64 yuan in Beijing Mabworks Biotech Co., Ltd. through a private placement, holding 2,095,558 shares[78] - The company's total raised funds amounted to 1,001,999,913.43 yuan, with a net amount of 995,405,374.70 yuan, and a cumulative usage of 68,991.37 million yuan[79] - The company used up to 300 million yuan of idle raised funds to temporarily supplement working capital, with a usage period not exceeding 12 months, and the full amount was returned to the raised funds special account by December 9, 2023[80] - As of December 31, 2023, the balance of idle raised funds used to temporarily supplement working capital was 260 million yuan[80] - The new drug R&D and R&D equipment upgrade project had a total investment commitment of 742 million yuan, with 58.83% (436.51 million yuan) invested by the end of the reporting period[81] - The supplementary working capital project had a total investment commitment of 260 million yuan, with 100% (253.41 million yuan) invested by the end of the reporting period[81] - The CM082 combined with JS001 for mucosal melanoma treatment clinical phase III project was suspended due to insufficient clinical advantages and inability to gain commercial competitive advantage in the current market environment[81] - The company used 176.58 million yuan of raised funds to replace pre-invested self-raised funds in the fundraising projects and paid issuance costs[81] - As of December 31, 2023, the unused raised funds were stored in the company's raised funds special account, with a balance of 260 million yuan temporarily supplementing working capital[82] - BPI-16350 project received RMB 127.5057 million in funding for Phase III clinical trials targeting HR-positive/HER2-negative advanced breast cancer[83][84] - The investment progress for BPI-16350 reached 62.90% with RMB 80.2009 million cumulatively invested by the end of the reporting period[83] - Hydrochloric acid ensartinib capsule project received RMB 60 million for Phase III clinical trials targeting ALK-positive NSCLC postoperative adjuvant treatment[83][84] - The investment progress for hydrochloric acid ensartinib capsule project reached 21.49% with RMB 12.8927 million cumulatively invested by the end of the reporting period[83] - X-396 project funding was reduced as it completed Phase III clinical trials and received approval for market launch[84] - CM082 combined with JS001 project funding was reduced due to insufficient clinical advantages and lack of commercial competitiveness[84] - MIL60 project funding was reduced as it completed Phase III clinical trials and received approval for market launch[84] - Total adjusted funding for new drug R&D projects amounted to RMB 187.5057 million[83] - Xcovery Holdings, Inc., a subsidiary, reported a net loss of RMB 199.3499 million[85] Product Portfolio and R&D - The company's main products include "Kemena" (Icotinib Hydrochloride Tablets), "Beimena" (Ensartinib), "Beianting" (Bevacizumab Injection), "Saimena" (Befotertinib Mesylate Capsules), and "Fumena" (Vorolanib Tablets)[4] - The company's Beijing and Hangzhou R&D centers are subsidiaries focused on new drug development[4] - The company's main business is the development and production of anti-tumor drugs, including small molecule and large molecule drugs[4] - The company's products are mainly used for the treatment of non-small cell lung cancer (NSCLC) and other cancers[4] - The company has successfully commercialized five new drugs, including Kaimeina, Beimeina, and Saimeina, which have become new revenue growth drivers[22] - The company has established a strong position in the lung cancer treatment field, with Kaimeina being the first domestically developed small molecule lung cancer targeted drug in China[21] - The company has also achieved a breakthrough in the kidney cancer treatment field with the launch of Fumeina, the first domestically developed anti-angiogenic drug in China[21] - The company's R&D pipeline focuses on unmet clinical needs in the field of malignant tumor treatment, particularly lung cancer[21] - The company's strategy includes academic promotion and real-world research to meet the treatment needs of experts and patients[21] - The company aims to build differentiated product advantages and promote more products to achieve successful commercialization[21] - Kemena (Icotinib) achieved a median DFS of 47.0 months vs. 22.1 months in the chemotherapy group for II-IIIA stage NSCLC patients with EGFR mutations[25] - Kemena reduced the risk of disease recurrence by 77% in completely resected IB stage NSCLC patients compared to the observation group[25] - Kemena's 3-year DFS rate was 63.9% vs. 32.5% in the chemotherapy group for II-IIIA stage NSCLC patients[25] - Bemnax (Ensartinib) showed a median PFS of 41.5 months in the overall population and 47.1 months in the non-brain metastasis population for ALK-positive NSCLC[24] - Bemnax's new drug application for first-line treatment of ALK-positive NSCLC was accepted by the US FDA[24] - Saimena (Furmonertinib) achieved a median PFS of 22.1 months in first-line treatment and 16.6 months in second-line treatment for EGFR-mutated NSCLC[24] - Saimena's median OS in second-line treatment reached 31.5 months, with an ORR of 92.3% in patients with baseline brain metastases[24] - Fumena (Fruquintinib) combined with everolimus achieved a median PFS of 10 months and a median OS of 30.4 months in advanced RCC patients[24] - Kemena has been involved in over 100 clinical studies and published 259 SCI papers with a total impact factor of 1,086.97[25] - Kemena was included in the National Reimbursement Drug List (NRDL) for all its approved indications[25] - Envonalkib (Bemena) has achieved a median PFS of 41.5 months in the Asian population, with a 4-year OS rate of 75.7% in the baseline non-brain metastasis group[27] - Envonalkib (Bemena) demonstrated a median PFS of 23.9 months in patients with baseline brain metastasis[27] - Envonalkib (Bemena) showed a median OS of 42.8 months in patients with advanced crizotinib-resistant NSCLC[27] - Envonalkib (Bemena) has published 64 articles with a total impact factor of nearly 400 points[27] - Envonalkib (Bemena) has completed enrollment for Phase II-IIIB in postoperative adjuvant therapy trials in China[26] - Envonalkib (Bemena) has submitted a new drug application for first-line treatment to the US FDA in March 2024[26] - Bevacizumab (Beianting) demonstrated an ORR of 48.6% at 12 weeks, equivalent to Avastin[28] - Bevacizumab (Beianting) has published 3 SCI papers with a total impact factor of 24.23 points[29] - BPI-D0316 (Saimeina) is a novel third-generation EGFR-TKI with independent intellectual property rights[30] - Saimena (Befotertinib) achieved a median PFS of 22.1 months in the IBIO-103 study, significantly higher than the 13.8 months in the Icotinib group[31] - Saimena's median PFS for patients with baseline brain metastasis was 19.4 months, compared to 13.7 months in the Icotinib group[31] - Saimena has been included in the National Reimbursement Drug List and has published 5 SCI papers with a total impact factor of 116.66[31] - Fumena (Vorolanib) combined with Everolimus showed a median PFS of 10.0 months, significantly better than the 6.4 months in the Everolimus monotherapy group[33] - Fumena combined with Everolimus achieved an ORR of 24.8%, significantly higher than the 8.3% in the Everolimus monotherapy group[33] - Fumena has published 17 SCI papers with a total impact factor of 74.06 and has been presented at international conferences[33] - EYP-1901, a sustained-release formulation of Vorolanib, reduced injection frequency by 89% and 85% in the 2mg and 3mg dose groups, respectively[33] - 65% and 64% of patients in the EYP-1901 2mg and 3mg dose groups did not require anti-VEGF rescue therapy for six months[33] - The company has established a leading domestic R&D system with centers in Beijing and Hangzhou, focusing on unmet clinical needs[35] - The company adheres to GMP standards throughout the entire production process, ensuring stable product quality[37] - R&D investment in 2023 was 1.00 billion yuan, accounting for 40.80% of revenue[41] - Kaimeina (凯美纳) extended its product lifecycle with stable sales, supported by strong clinical data[40] - Beimeina (贝美纳) saw rapid sales growth after being included in the National Reimbursement Drug List (NRDL) in 2023[40] - New products Saimeina (赛美纳) and Fumeina (伏美纳) were approved and included in the NRDL, contributing to revenue growth[40] - The company has 5 marketed products, with 4 included in the NRDL, diversifying revenue sources[48] - Strategic collaborations with companies like TianGuangShi and EYPT enriched the R&D pipeline[45] - R&D investment in 2023 reached RMB 10,020.505 million, accounting for 40.80% of total revenue, driving pipeline growth and achieving milestones[49] - 5 products are now on the market, with 4 included in the National Reimbursement Drug List (NRDL)[49] - BPI-16350 Phase III clinical study completed patient enrollment in April 2023, showing a confirmed ORR of 60.5% with good safety[49] - 10 drug candidates/indications received clinical trial approvals in 2023, including TEAD inhibitor BPI-460372 approved for clinical studies in both China and the US[49] - CFT8919 exclusive rights in China secured with a $10 million upfront payment, and $25 million invested in C4T for 5,567,928 shares[51] - RMB 21 million invested in Hangzhou Guoshun Jianheng Venture Capital Partnership, with the company contributing RMB 4 million (19.05%)[51] - Production of all batches in 2023 achieved a 100% qualification rate, ensuring stable supply for commercial and clinical use[52] - BPI-442096, BPI-371153, BPI-361175, BPI-452080, BPI-460372, and BPI-21668 clinical trial drug supplies were delivered as planned[53] - Ensartinib (ALK inhibitor) NDA for NSCLC treatment accepted by the US FDA, currently under review[54] - Caimena and Baimena maintained in the NRDL, while Samena and Fumena were newly included in 2023[54] - The company's main products include Icotinib Hydrochloride Tablets, Ensartinib Hydrochloride Capsules, Befotertinib Mesylate Capsules, and Vorolanib Tablets, all of which are protected by patents until at least 2027[55] - The company has multiple R&D projects in Phase III clinical trials, including BPI-16350 and BPI-D0316, which are expected to contribute to future revenue growth[65] - The company decided to suspend the development of BPI-43487 and BPI-421286 due to insufficient clinical advantages[66] Corporate Governance and Shareholder Information - The company's profit distribution plan for 2023 is to distribute a cash dividend of 1.7 yuan per 10 shares (tax included) based on 418,485,885 shares[3] - The company's registered address was changed to No. 355 Xingzhong Road, Economic and Technological Development Zone, Linping District, Hangzhou, Zhejiang Province on December 12, 2023[6] - The company's stock code is 300558, and its legal representative is Ding Lieming[6] -

证券代码：300558 证券简称：贝达药业 公告编号：2024-017 1、本次监事会会议通知于 2024 年 4 月 3 日以电子邮件、电话等形式送达全 体监事，监事会会议通知中包括会议的相关材料，同时列明了会议的召开时间、 地点、内容和方式。 2、本次监事会于 2024 年 4 月 18 日在公司杭州总部 3 楼会议室采取现场会议 的方式召开，现场投票表决。 3、本次监事会应到 3 人，实际出席会议人数为 3 人。 4、本次监事会由张洋南先生主持，公司证券事务代表沈剑豪先生列席了本 次会议。 贝达药业股份有限公司 第四届监事会第十一次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以 下简称"《公司法》"）等法律法规和《贝达药业股份有限公司章程》（以下简 称"《公司章程》"）的有关规定。 二、监事会会议审议情况 会议审议并通过了如下议案： 1、审议通过《2023 年度监事会工作报告》 经审议，监事会通过了《2023 年度监事会工作报告》。 表决结果：同意 ...

证券代码：300558 证券简称：贝达药业 公告编号：2024-025 1 二、担保额度预计 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 为满足公司业务发展需要，贝达药业股份有限公司（以下简称"公司"或 "贝达药业"）于 2024 年 4 月 18 日召开的第四届董事会第十三次会议审议通过 了《关于公司及子公司申请综合融资额度及为融资额度内部分融资提供担保的议 案》，同意公司及下属子公司卡南吉医药科技（上海）有限公司、浙江贝达诊断 技术有限公司、贝达梦工场控股有限公司、贝达梦工场（杭州）创新科技有限公 司、贝达梦工场（浙江）医药控股有限公司（以下简称"贝梦医药"）、贝达药 业（嵊州）有限公司、贝达生物医药科技（浙江）有限公司、Xcovery Holdings, Inc.、Equinox Sciences, LLC 、贝达投资（香港）有限公司、Xcovery Betta Pharmaceuticals, Inc.、Meryx Inc.申请融资总额不超过 30 亿元人民币，融资起始 期限自 2023 年度股东大会审议通过本议案之日起 12 个 ...

贝达药业股份有限公司董事会审计委员会 关于对会计师事务所 2023 年度履职情况的评估报告 公司聘请立信会计师事务所（特殊普通合伙）（以下简称"立信"）作为公 司 2023 年度审计机构。根据财政部、国资委及证监会颁布的《国有企业、上市 公司选聘会计师事务所管理办法》，公司对立信 2023 年审计过程中的履职情况 进行评估。经评估，公司认为立信资质等方面合规有效，履职保持独立性，勤勉 尽责，公允表达意见，具体情况如下： 一、资质条件 立信会计师事务所（特殊普通合伙）由我国会计泰斗潘序伦博士于 1927 年 在上海创建，1986 年复办，2010 年成为全国首家完成改制的特殊普通合伙制会 计师事务所，注册地址为上海市，首席合伙人为朱建弟先生。立信是国际会计网 络 BDO 的成员所，长期从事证券服务业务，新证券法实施前具有证券、期货业 务许可证，具有 H 股审计资格，并已向美国公众公司会计监督委员会（PCAOB） 注册登记。 二、执业记录 1、基本信息 | 项目 | 姓名 | 注册会计师执 | 开始从事上市 | 开始在本所执 | 开始为本公司提 | | --- | --- | --- | --- | --- | ...